Posted by Michael Wonder on 24 Sep 2022
FDA grants rare paediatric disease designation to dovitinib for osteosarcoma
22 September 2022 - Rare paediatric disease designation qualifies Oncoheroes to receive fast track review, and a priority review voucher at the time of marketing approval of dovitinib.
Oncoheroes Biosciences is pleased to announce that the US FDA has granted the designation of rare paediatric disease to dovitinib, an investigational treatment for osteosarcoma.
